Trials / Terminated
TerminatedNCT04381988
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | 400mg daily |
| OTHER | Placebo | 400mg daily |
| RADIATION | Radiation therapy | Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist. |
Timeline
- Start date
- 2020-05-07
- Primary completion
- 2021-04-21
- Completion
- 2021-04-21
- First posted
- 2020-05-11
- Last updated
- 2021-10-27
- Results posted
- 2021-10-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04381988. Inclusion in this directory is not an endorsement.